Biblio

Author Title [ Type

] Year

Filters: Author is Epperla, Narendranath [Clear All Filters]

Journal Article

Badar T, Epperla N, Szabo A, Borson S, Vaughn J, George G, Saini N, Shah ARashid, Patel RD, Ahmed S, et al. Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Adv. 2020;4(1):47-54.

Vaughn JL, Soroka O, Epperla N, Safford M, Pinheiro LC. Racial and ethnic differences in the utilization of autologous transplantation for lymphoma in the United States. Cancer Med. 2021.

Ahmed S, Zhao Q, Hanel W, Qazilbash MH, Patel K, Narra R, Kansagra A, Iqbal M, Awan FT, Christian B, et al. Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. Hematol Oncol. 2021.

Denlinger N, Song N-J, Zhang X, Jeon H, Peterson C, Wang Y, Reynolds K, Bolz R, Miao J, Song C, et al. Post-infusion PD-1+CD8+CAR-T cells identify patients responsive to CD19-CAR-T therapy in non-Hodgkin's lymphoma. Blood Adv. 2024.

David KA, Sundaram S, Kim S-H, Vaca R, Lin Y, Singer S, Malecek M-K, Carter J, Zayac A, Kim MSun, et al. Older Patients with Primary Central Nervous System Lymphoma: Survival and Prognostication Across 20 US Cancer Centers. Am J Hematol. 2023.

Epperla N, Ahn KW, Khanal M, Litovich C, Ahmed S, Ghosh N, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M. Impact of reduced-intensity conditioning regimens on outcomes in diffuse large B-cell lymphoma undergoing allogeneic transplantation. Biol Blood Marrow Transplant. 2020.

Ravandi F, Kreitman RJ, Tiacci E, Andritsos L, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call T, et al. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer J. 2022;12(12):165.

Jain N, Mamgain M, Chowdhury SMullick, Jindal U, Sharma I, Sehgal L, Epperla N. Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel agents. J Hematol Oncol. 2023;16(1):99.